Have a question?
Please get in touch with our team in case of any queries
THE U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE WAS VALUED AT USD 3.05 BILLION IN 2021 AND IS EXPECTED TO REACH USD 4.55 BILLION BY 2027, GROWING AT A CAGR OF 6.90% DURING THE FORECAST PERIOD
The U.S. Assisted Reproductive Technology Market Research Report Includes Size, Share, Trends Analysis, Competitive Landscape, and Growth Potential
- Type
- Services
- Source: Frozen Non-Donor, Fresh Non-Donor, Fresh Donor and Frozen Donor
- Age Group: Between 35 & 40 Years, Less Than 35 Years and Above 40 Years
- Technique: In Virto Fertilization (IVF), Frozen Embryo Transfer (FET), and Others
- Devices
- Product: Consumables, Media, and Equipment
- End-User: Fertility Clinics and Hospitals
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2027) | USD 4.55 BILLION |
| Market Size (2021) | USD 3.05 BILLION |
| CAGR (2021-2027) | 6.90% |
| Base Year | 2021 |
| Historic Year | |
| Forecast Year | 2022-2027 |
| Market Segments | Type, Services, and Devices |
| Geographic Analysis | United States |
| Countries Covered |
MARKET INSIGHTS
The U.S. assisted reproductive technology market is expected to grow at a CAGR of over 6% from 2022 to 2027 and is expected to cross $4 billion by 2027 from $3 billion in 2021. Assisted reproductive technology (ART) is used for the treatment of infertility. It involves fertility treatments that handle both a man’s sperm and a woman’s egg. ART works by detaching eggs from a woman’s body. Then, the eggs are mixed with sperm to make embryos. Most of the time, ART procedures consist of surgically taking off the eggs from a woman’s ovaries, blending them with sperm in the laboratory, and then returning them to the woman’s body or donating them to another woman. The major factors propelling the growth of the U.S. assisted reproductive technology industry is the increasing prevalence of infertility, changing lifestyle of people causing infertility, the growing acceptance of ART procedure, and the rising number of fertility clinics.
Constant product innovations, technological advancements, and increasing end-user awareness drive the industry's growth. The significant players adopt several expansion and growth strategies such as partnerships, acquisitions, and product launches to increase their market presence. Perceiving a lucrative market, private equity firms are flowing money into building national chains of fertility clinics. The entry of venture capitalists and private equity is changing the overall fertility services industry. According to Arizton’s report, the global fertility test market was valued at USD 439.56 million in 2021 and is expected to grow at a CAGR of 7%. The globalization of healthcare facilities and the increasing popularity of fertility tourism are significant growth enablers of the global infertility treatment market.
TRENDS AND DEVELOPMENT
- The growing number of single parents and same-sex couples is driving the growth of assisted reproductive technology market in the U.S. Governments of various countries are legalizing infertility treatment for same-sex couples and single parents.
- Technological advancements and innovations in ART contribute to the United States assisted reproductive technology market growth. For instance, medical laser technology is now being employed across ART to decrease the procedure times and enhance conventional ART techniques' consistency and reproducibility.
- Rising venture capital & private equity investment in infertility services drive the U.S. assisted reproductive technology industry. In 2017 alone, over 75 fertility-related firms received USD 178 million from private investors to grow Assisted Reproductive Technology Global Market.
- Increasing financial assistance programs & employer benefits for infertility treatment contributes to industry growth. Many employers pay greater attention to personal health issues, especially infertility among employees, and offer various benefits, not just fertility leaves but also fertility allowances to get infertility treated.
MARKET SHARE & SEGMENTS
The frozen non-donor segment accounted for a significant share of more than 50% in 2021. The substantial share growth is due to fertility clinics' increased awareness of egg-freezing techniques among infertile couples. The IVF segment accounted for more than 80% share by technique because of its low-risk factor. Consumption growth is attributed to the increased and recurring usage of consumables during IVF procedures.
The fertility Clinics segment accounted for more than 70% of the US assisted reproductive technology market in 2021. The number of fertility clinics is increasing globally as the acceptance of fertility services is growing and at an all-time high in most countries. This increase in fertility clinics is catering to the growing demand for fertility services like IVF procedures among patients with infertility problems.
COMPETITIVE LANDSCAPE
- The key players in assisted reproductive technology (ART) market are The Cooper Companies, Cook Medical, FUJIFILM Irvine Scientific, Hamilton Thorne, Merck Group, and Vitrolife.
- Vendors may depend on strategic collaborations with end-users offering IVF procedures to promote their new products and establish long-term associations with their customers.
- Key players with huge infrastructure and R&D support are expanding their footprint in the industry by implementing various marketing strategies to gain traction among end-users and increase their market presence.
- Vendors should seek to strengthen their distribution by establishing company-owned distribution or sales networks or forming license or distribution contracts with regional vendors to expand product profit margins.
The U.S. assisted reproductive technology market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
Segmentation
- Type
- Services
- Source
- Frozen Non-Donor
- Fresh Non-Donor
- Fresh Donor
- Frozen Donor
- Age Group
- Between 35 & 40 Years
- Less Than 35 Years
- Above 40 Years
- Technique
- In Virto Fertilization (IVF)
- Frozen Embryo Transfer (FET)
- Others
- Source
- Devices
- Product
- Consumables
- Media
- Equipment
- End-user
- Fertility Clinics
- Hospitals
- Product
KEY INDUSTRY PLAYERS
- Cook Medical
- FUJIFILM Irvine Scientific
- Hamilton Thorne
- Merck Group
- Vitrolife
SNAPSHOT
The U.S. assisted reproductive technology (ART) market was valued at USD 3,050.0 million in 2021 and is expected to reach USD 4,551.53 million by 2027, growing at a CAGR of 6.90% during the forecast period.
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present U.S. assisted reproductive technology (ART) market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
KEY MANUFACTURERS PROFILE
- The Cooper Companies
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- Cook Medical
- FUJIFILM Irvine Scientific
- Hamilton Thorne
- Merck Group
- Vitrolife
OTHER PROMINENT MANUFACTURERS
- CARL ZEISS
- Business Overview
- Product Offerings
- Esco Lifesciences
- INVO Bioscience
- Kitazato USA
- Nidacon
- Rocket Medical
- Thermo Fisher Scientific
- Thomas Medical
PROMINENT ART SERVICE PROVIDERS
- The American Fertility California Corp.
- Business Overview
- Product Offerings
- Angels Creation Reproductive Center (ACRC)
- Aspire Houston Fertility Institute
- Boston IVF
- CARE Fertility
- Carolinas Fertility Institute
- CCRM Fertility
- Center of Reproductive Medicine
- Conceptions Reproductive Associates
- Dallas-Fort Worth Fertility Associates
- Extend Fertility
- Fertility Center
- Fertility Center of San Antonio
- Infertility Texas
- Innovative Fertility Center
- Institute for Human Reproduction (IHR)
- Kindbody
- Main Line Fertility & Reproductive Medicine
- Mayo Clinic
- New Hope Fertility Center
- Oma Fertility
- Overlake Reproductive Health
- Pacific Fertility Center
- Pacific Reproductive Center
- Reproductive Medicine Associates of Philadelphia
- ReproMed Fertility Center
- San Diego Fertility Center
- Santa Barbara Fertility Center
- Santa Monica Fertility
- Sher Institutes for Reproductive Medicine
- Southern California Reproductive Center (SCRC)
- Tennessee Reproductive Medicine (TRM)
- Texas Center for Reproductive Health
- The Center for Fertility and Gynecology
- The Fertility Center of Las Vegas
- The Reproductive Medicine Group
- UCLA Fertility and Reproductive Health Center
- Western Fertility Institute
- Wisconsin Fertility
Segmentation
- Type
- Services
- Source
- Frozen Non-Donor
- Fresh Non-Donor
- Fresh Donor
- Frozen Donor
- Age Group
- Between 35 & 40 Years
- Less Than 35 Years
- Above 40 Years
- Technique
- In Virto Fertilization (IVF)
- Frozen Embryo Transfer (FET)
- Others
- Source
- Devices
- Product
- Consumables
- Media
- Equipment
- End-user
- Fertility Clinics
- Hospitals
- Product
Frequently Asked Questions
What is the total market worth of assisted reproductive technology market in U.S.?
Which are the top manufacturers that hold the major share in assisted reproductive technology market in United States?
What are the key trends in the U.S. assisted reproductive technology (ART) market report?
What are some market opportunities for emerging players to increase their industry share?
What is the anticipated CAGR of the assisted reproductive technology market in the forecast period?
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 SOME FACTS ABOUT CONCEPTION AND FERTILITY
EXHIBIT 4 IMPACT OF GROWING NUMBER OF SINGLE PARENTS AND SAME-SEX COUPLES
EXHIBIT 5 SAME-SEX MARRIED COUPLES IN THE US DURING 2010-2019
EXHIBIT 6 IMPACT OF TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN ART
EXHIBIT 7 IMPACT OF RISING VENTURE CAPITAL & PRIVATE EQUITY INVESTMENTS IN INFERTILITY SERVICES
EXHIBIT 8 IMPACT OF INCREASING FINANCIAL ASSISTANCE PROGRAMS & EMPLOYER BENEFITS FOR INFERTILITY TREATMENT
EXHIBIT 9 IMPACT OF INCREASING PREVALENCE OF INFERTILITY
EXHIBIT 10 IMPACT OF RISING NUMBER OF FERTILITY CLINICS OFFERING FERTILITY SERVICES
EXHIBIT 11 IMPACT OF CHANGING LIFESTYLES OF PEOPLE
EXHIBIT 12 IMPACT OF INCREASING ACCEPTANCE OF ART PROCEDURES
EXHIBIT 13 NUMBER OF ART CYCLES PERFORMED IN THE US 2012-2029 (IN 1,000S)
EXHIBIT 14 PERCENTAGE OF INFANTS BORN FROM ART PROCEDURES PERFORMED IN 2017 WHO WERE PRETERM OR WITH LOW BIRTH WEIGHT—US 2017 OR 2018
EXHIBIT 15 IMPACT OF HIGH COST OF INFERTILITY TREATMENT
EXHIBIT 16 IMPACT OF RISKS AND LIMITATIONS ASSOCIATED WITH INFERTILITY TREATMENT
EXHIBIT 17 ETHICAL CHALLENGES RELATED TO INFERTILITY TREATMENTS
EXHIBIT 18 ETHICAL AND LEGAL CHALLENGES
EXHIBIT 19 IMPACT OF LACK OF STANDARDIZED GOVERNMENT REGULATIONS ON INFERTILITY TREATMENT
EXHIBIT 20 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 2021–2027 ($ MILLION)
EXHIBIT 21 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE
EXHIBIT 22 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY SOURCE
EXHIBIT 23 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY AGE GROUP
EXHIBIT 24 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY TECHNIQUE
EXHIBIT 25 US ASSISTED REPRODUCTIVE TECHNOLOGY DEVICES MARKET BY PRODUCT
EXHIBIT 26 US ASSISTED REPRODUCTIVE TECHNOLOGY DEVICES MARKET BY END-USER
EXHIBIT 27 FIVE FORCES ANALYSIS 2021
EXHIBIT 28 INCREMENTAL GROWTH BY TYPE 2021 & 2027
EXHIBIT 29 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE
EXHIBIT 30 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE: INCREMENTAL GROWTH
EXHIBIT 31 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY SERVICES
EXHIBIT 32 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY SERVICES 2021–2027 ($ MILLION)
EXHIBIT 33 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 34 US ART SERVICES FROZEN NON-DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 35 US ART SERVICES FROZEN NON-DONOR MARKET 2021–2027 ($ MILLION)
EXHIBIT 36 US ART SERVICES FRESH NON-DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 US ART SERVICES FRESH NON-DONOR MARKET 2021–2027 ($ MILLION)
EXHIBIT 38 US ART SERVICES FRESH DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 US ART SERVICES FRESH DONOR MARKET 2021–2027 ($ MILLION)
EXHIBIT 40 US ART SERVICES FROZEN DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 US ART SERVICES FROZEN DONOR MARKET 2021–2027 ($ MILLION)
EXHIBIT 42 INCREMENTAL GROWTH BY AGE GROUP 2021 & 2027
EXHIBIT 43 US ART SERVICES BETWEEN 35 & 40 YEARS OF AGE MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 US ART SERVICES BETWEEN 35 & 40 YEARS OF AGE MARKET 2021–2027 ($ MILLION)
EXHIBIT 45 US ART SERVICES LESS THAN 35 YEARS OF AGE MARKET 2021–2027 ($ MILLION)
EXHIBIT 46 US ART SERVICES ABOVE 40 YEARS OF AGE MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 47 PERCENTAGE OF LIVE BIRTHS PER CYCLE IN WOMEN 40 YEARS & ABOVE
EXHIBIT 48 US ART SERVICES ABOVE 40 YEARS OF AGE MARKET 2021–2027 ($ MILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY TECHNIQUE 2021 & 2027
EXHIBIT 50 US ART SERVICES IN VITRO FERTILIZATION (IVF) MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 IVF OVERVIEW
EXHIBIT 52 INFERTILITY PROBLEMS FOR WHICH IVF MAY BE REQUIRED
EXHIBIT 53 US ART SERVICES IN VITRO FERTILIZATION (IVF) MARKET 2021–2027 ($ MILLION)
EXHIBIT 54 US ART SERVICES FROZEN EMBRYO TRANSFER (FET) MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 US ART SERVICES FROZEN EMBRYO TRANSFER (FET) MARKET 2021–2027 ($ MILLION)
EXHIBIT 56 US ART SERVICES OTHER TECHNIQUES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 US ART SERVICES OTHER TECHNIQUES MARKET 2021–2027 ($ MILLION)
EXHIBIT 58 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY DEVICES
EXHIBIT 59 US ART DEVICES MARKET 2021–2027 ($ MILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 61 US ART DEVICES CONSUMABLES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 US ART DEVICES CONSUMABLES MARKET 2021–2027 ($ MILLION)
EXHIBIT 63 US ART DEVICES MEDIA MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 US ART DEVICES MEDIA MARKET 2021–2027 ($ MILLION)
EXHIBIT 65 US ART DEVICES EQUIPMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 US ART DEVICES EQUIPMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 68 US ART DEVICES FERTILITY CLINICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 US ART DEVICES FERTILITY CLINICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 70 US ART DEVICES HOSPITALS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 US ART DEVICES HOSPITALS MARKET 2021–2027 ($ MILLION)
EXHIBIT 72 THE COOPER COMPANIES: ANNUAL REVENUES 2019-2021 ($ MILLION)
EXHIBIT 73 THE COOPER COMPANIES BUSINESS SEGMENTS: ANNUAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 74 THE COOPERS COMPANIES REVENUE SPLIT: COOPERSURGICAL BUSINESS SEGMENT 2020 (%)
EXHIBIT 75 MERCK GROUP: ANNUAL REVENUE 2018-2020 ($ BILLION)
EXHIBIT 76 MERCK GROUP BUSINESS SEGMENTS: ANNUAL REVENUE 2019-2020 ($ MILLION)
EXHIBIT 77 VITROLIFE: ANNUAL REVENUE 2018-2020 ($ MILLION)
EXHIBIT 78 VITROLIFE BY REGION: SALES REVENUE 2019-2020 ($ MILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 SOME POPULAR FERTILITY TREATMENT LOANS IN THE US
TABLE 4 SOME OF THE MOST PREVALENT FERTILITY TREATMENT GRANTS IN THE US
TABLE 5 FERTILITY RELATED CONDITIONS ASSOCIATED WITH OBESITY IN MEN
TABLE 6 FERTILITY RELATED CONDITIONS RELATED TO OBESITY IN FEMALES
TABLE 7 PROBABILITIES OF A LIVE BIRTH BY FIFTH IVF CYCLE
TABLE 8 COSTS OF VARIOUS INFERTILITY TREATMENT OPTIONS
TABLE 9 TOP FIVE IVF CLINICS FOR WOMEN AGED UNDER 35 (NON-DONOR EGGS)
TABLE 10 TOP FIVE IVF CLINICS FOR WOMEN AGED OVER 42 (NON-DONOR EGGS)
TABLE 11 ART CLINICAL OUTCOMES IN WOMEN ABOVE 40 YEARS
TABLE 12 AVERAGE IVF SUCCESS RATE IN THE US FOR FRESH EMBRYOS
TABLE 13 AVERAGE IVF SUCCESS RATE IN THE US FOR THAWED EMBRYOS
TABLE 14 SOME PROMINENT PLAYERS IN THE ART DEVICES MARKET OFFERING CONSUMABLES
TABLE 15 MEDIA OFFERINGS BY MAJOR PLAYERS
TABLE 16 TYPES OF MICROSCOPES USED IN ART PROCEDURES
TABLE 17 VARIOUS TYPES OF IMAGING MODALITIES USED IN ART PROCEDURES
TABLE 18 LIST OF TOP FERTILITY CLINICS IN THE US
TABLE 19 THE COOPER COMPANIES: PRODUCT OFFERINGS
TABLE 20 COOK MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 21 FUJIFILM IRVINE SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 22 HAMILTON THORNE: MAJOR PRODUCT OFFERINGS
TABLE 23 MERCK GROUP: MAJOR PRODUCT OFFERINGS
TABLE 24 VITROLIFE: MAJOR PRODUCT OFFERINGS
TABLE 25 CARL ZEISS: MAJOR PRODUCT OFFERINGS
TABLE 26 ESCO LIFESCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 27 INVO BIOSCIENCE: MAJOR PRODUCT OFFERINGS
TABLE 28 KITAZATO: MAJOR PRODUCT OFFERINGS
TABLE 29 NIDACON: MAJOR PRODUCT OFFERINGS
TABLE 30 ROCKET MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 31 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 32 THOMAS MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 33 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE 2021−2027 ($ MILLION)
TABLE 34 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE 2021−2027 (%)
TABLE 35 US ART SERVICES MARKET BY SOURCE 2021−2027 ($ MILLION)
TABLE 36 US ART SERVICES MARKET BY SOURCE 2021−2027 (%)
TABLE 37 US ART SERVICES MARKET BY AGE GROUP 2021−2027 ($ MILLION)
TABLE 38 US ART SERVICES MARKET BY AGE GROUP 2021−2027 (%)
TABLE 39 US ART SERVICES MARKET BY TECHNIQUE 2021−2027 ($ MILLION)
TABLE 40 US ART SERVICES MARKET BY TECHNIQUE 2021−2027 (%)
TABLE 41 US ART DEVICES MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 42 US ART DEVICES MARKET BY PRODUCT 2021−2027 (%)
TABLE 43 US ART DEVICES MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 44 US ART DEVICES MARKET BY END-USER 2021−2027 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY SERVICE
4.3.2 MARKET SEGMENTATION BY DEVICE
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW OF INFERTILITY & ART
7.2 TRENDS IN ART
8 MARKET OPPORTUNITIES & TRENDS
8.1 GROWING NUMBER OF SINGLE PARENTS AND SAME-SEX COUPLES
8.2 TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN ART
8.3 RISING VENTURE CAPITAL & PRIVATE EQUITY INVESTMENTS IN INFERTILITY SERVICES
8.4 INCREASING FINANCIAL ASSISTANCE PROGRAMS & EMPLOYER BENEFITS FOR INFERTILITY TREATMENT
9 MARKET GROWTH ENABLERS
9.1 INCREASING PREVALENCE OF INFERTILITY
9.2 RISING NUMBER OF FERTILITY CLINICS OFFERING FERTILITY SERVICES
9.3 CHANGING LIFESTYLES OF PEOPLE
9.4 INCREASING ACCEPTANCE OF ART PROCEDURES
10 MARKET RESTRAINTS
10.1 HIGH COST OF INFERTILITY TREATMENT
10.2 RISKS AND LIMITATIONS ASSOCIATED WITH INFERTILITY TREATMENT
10.3 ETHICAL CHALLENGES RELATED TO INFERTILITY TREATMENT
10.4 LACK OF STANDARDIZED GOVERNMENT REGULATIONS ON INFERTILITY TREATMENT
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 TYPE INSIGHTS
11.2.2 SOURCE INSIGHTS
11.2.3 AGE GROUP INSIGHTS
11.2.4 TECHNIQUE INSIGHTS
11.2.5 PRODUCT INSIGHTS
11.2.6 END-USER INSIGHTS
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 TYPE
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
13 SERVICES
13.1 MARKET OVERVIEW
13.2 MARKET SIZE & FORECAST
13.3 ART SERVICES MARKET BY SOURCE
13.3.1 MARKET SNAPSHOT & GROWTH ENGINE
13.4 FROZEN NON-DONOR
13.4.1 MARKET SIZE & FORECAST
13.5 FRESH NON-DONOR
13.5.1 MARKET SIZE & FORECAST
13.6 FRESH DONOR
13.6.1 MARKET SIZE & FORECAST
13.7 FROZEN DONOR
13.7.1 MARKET SIZE & FORECAST
13.8 ART SERVICES MARKET BY AGE GROUP
13.8.1 MARKET SNAPSHOT & GROWTH ENGINE
13.9 BETWEEN 35 & 40 YEARS
13.9.1 MARKET SIZE & FORECAST
13.10 LESS THAN 35 YEARS
13.10.1 MARKET SIZE & FORECAST
13.11 ABOVE 40 YEARS
13.11.1 MARKET SIZE & FORECAST
13.12 ART SERVICES MARKET BY TECHNIQUE
13.12.1 MARKET SNAPSHOT & GROWTH ENGINE
13.13 IN VITRO FERTILIZATION (IVF)
13.13.1 MARKET SIZE & FORECAST
13.14 FROZEN EMBRYO TRANSFER (FET)
13.14.1 MARKET SIZE & FORECAST
13.15 OTHERS
13.15.1 MARKET SIZE & FORECAST
14 DEVICES
14.1 MARKET OVERVIEW
14.2 MARKET SIZE & FORECAST
14.3 ART DEVICES MARKET BY PRODUCT
14.3.1 MARKET SNAPSHOT & GROWTH ENGINE
14.3.2 CONSUMABLES: MARKET SIZE & FORECAST
14.3.3 MEDIA: MARKET SIZE & FORECAST
14.3.4 EQUIPMENT: MARKET SIZE & FORECAST
14.4 ART DEVICES MARKET BY END-USER
14.4.1 MARKET SNAPSHOT & GROWTH ENGINE
14.4.2 FERTILITY CLINICS: MARKET SIZE & FORECAST
14.4.3 HOSPITALS: MARKET SIZE & FORECAST
15 COMPETITIVE LANDSCAPE
15.1 COMPETITION OVERVIEW: ART DEVICE MANUFACTURERS
15.2 COMPETITION OVERVIEW: SERVICE PROVIDERS
15.3 MARKET SHARE ANALYSIS: MANUFACTURERS
15.3.1 THE COOPER COMPANIES
15.3.2 COOK MEDICAL
15.3.3 VITROLIFE
15.3.4 FUJIFILM IRVINE SCIENTIFIC
15.3.5 ROCKET MEDICAL
15.3.6 KITAZATO
15.3.7 MERCK GROUP
15.3.8 HAMILTON THORNE
15.4 MARKET SHARE ANALYSIS: ART SERVICE PROVIDERS
16 KEY MANUFACTURER PROFILES
16.1 THE COOPER COMPANIES
16.1.1 BUSINESS OVERVIEW
16.1.2 MAJOR PRODUCT OFFERINGS
16.1.3 KEY STRENGTHS
16.1.4 KEY STRATEGIES
16.1.5 KEY OPPORTUNITIES
16.2 COOK MEDICAL
16.2.1 BUSINESS OVERVIEW
16.2.2 MAJOR PRODUCT OFFERINGS
16.2.3 KEY STRATEGIES
16.2.4 KEY STRENGTHS
16.2.5 KEY OPPORTUNITIES
16.3 FUJIFILM IRVINE SCIENTIFIC
16.3.1 BUSINESS OVERVIEW
16.3.2 MAJOR PRODUCT OFFERINGS
16.3.3 KEY STRATEGIES
16.3.4 KEY STRENGTHS
16.3.5 KEY OPPORTUNITIES
16.4 HAMILTON THORNE
16.4.1 BUSINESS OVERVIEW
16.4.2 MAJOR PRODUCT OFFERINGS
16.4.3 KEY STRATEGIES
16.4.4 KEY STRENGTHS
16.4.5 KEY OPPORTUNITIES
16.5 MERCK GROUP
16.5.1 BUSINESS OVERVIEW
16.5.2 MAJOR PRODUCT OFFERINGS
16.5.3 KEY STRATEGIES
16.5.4 KEY STRENGTHS
16.5.5 KEY OPPORTUNITIES
16.6 VITROLIFE
16.6.1 BUSINESS OVERVIEW
16.6.2 MAJOR PRODUCT OFFERINGS
16.6.3 KEY STRATEGIES
16.6.4 KEY STRENGTHS
16.6.5 KEY OPPORTUNITIES
17 OTHER PROMINENT MANUFACTURERS
17.1 CARL ZEISS
17.1.1 BUSINESS OVERVIEW
17.1.2 MAJOR PRODUCT OFFERINGS
17.2 ESCO LIFESCIENCES
17.2.1 BUSINESS OVERVIEW
17.2.2 MAJOR PRODUCT OFFERINGS
17.3 INVO BIOSCIENCE
17.3.1 BUSINESS OVERVIEW
17.3.2 MAJOR PRODUCT OFFERINGS
17.4 KITAZATO
17.4.1 BUSINESS OVERVIEW
17.4.2 MAJOR PRODUCT OFFERINGS
17.5 NIDACON
17.5.1 BUSINESS OVERVIEW
17.5.2 MAJOR PRODUCT OFFERINGS
17.6 ROCKET MEDICAL
17.6.1 BUSINESS OVERVIEW
17.6.2 MAJOR PRODUCT OFFERINGS
17.7 THERMO FISHER SCIENTIFIC
17.7.1 BUSINESS OVERVIEW
17.7.2 MAJOR PRODUCT OFFERINGS
17.8 THOMAS MEDICAL
17.8.1 BUSINESS OVERVIEW
17.8.2 MAJOR PRODUCT OFFERINGS
18 PROMINENT ART SERVICE PROVIDERS
18.1 THE AMERICAN FERTILITY CALIFORNIA CORP.
18.1.1 BUSINESS OVERVIEW
18.2 ANGELS CREATION REPRODUCTIVE CENTER
18.2.1 BUSINESS OVERVIEW
18.3 ASPIRE HOUSTON FERTILITY INSTITUTE
18.3.1 BUSINESS OVERVIEW
18.4 BOSTON IVF
18.4.1 BUSINESS OVERVIEW
18.5 CARE FERTILITY
18.5.1 BUSINESS OVERVIEW
18.6 CAROLINAS FERTILITY INSTITUTE
18.6.1 BUSINESS OVERVIEW
18.7 CCRM FERTILITY
18.7.1 BUSINESS OVERVIEW
18.8 CENTER OF REPRODUCTIVE MEDICINE
18.8.1 BUSINESS OVERVIEW
18.9 CONCEPTIONS REPRODUCTIVE ASSOCIATES
18.9.1 BUSINESS OVERVIEW
18.10 DALLAS-FORT WORTH FERTILITY ASSOCIATES
18.10.1 BUSINESS OVERVIEW
18.11 EXTEND FERTILITY
18.11.1 BUSINESS OVERVIEW
18.12 FERTILITY CENTER
18.12.1 BUSINESS OVERVIEW
18.13 FERTILITY CENTER OF SAN ANTONIO
18.13.1 BUSINESS OVERVIEW
18.14 INFERTILITY TEXAS
18.14.1 BUSINESS OVERVIEW
18.15 INNOVATIVE FERTILITY CENTER
18.15.1 BUSINESS OVERVIEW
18.16 INSTITUTE FOR HUMAN REPRODUCTION
18.16.1 BUSINESS OVERVIEW
18.17 KINDBODY
18.17.1 BUSINESS OVERVIEW
18.18 MAIN LINE FERTILITY & REPRODUCTIVE MEDICINE
18.18.1 BUSINESS OVERVIEW
18.19 MAYO CLINIC
18.19.1 BUSINESS OVERVIEW
18.20 NEW HOPE FERTILITY CENTER
18.20.1 BUSINESS OVERVIEW
18.21 OMA FERTILITY
18.21.1 BUSINESS OVERVIEW
18.22 OVERLAKE REPRODUCTIVE HEALTH
18.22.1 BUSINESS OVERVIEW
18.23 PACIFIC FERTILITY CENTER
18.23.1 BUSINESS OVERVIEW
18.24 PACIFIC REPRODUCTIVE CENTER
18.24.1 BUSINESS OVERVIEW
18.25 REPRODUCTIVE MEDICINE ASSOCIATES OF PHILADELPHIA
18.25.1 BUSINESS OVERVIEW
18.26 REPROMED FERTILITY CENTER
18.26.1 BUSINESS OVERVIEW
18.27 SAN DIEGO FERTILITY
18.27.1 BUSINESS OVERVIEW
18.28 SANTA BARBARA FERTILITY CENTER
18.28.1 BUSINESS OVERVIEW
18.29 SANTA MONICA FERTILITY
18.29.1 BUSINESS OVERVIEW
18.30 SHER INSTITUTES FOR REPRODUCTIVE MEDICINE
18.30.1 BUSINESS OVERVIEW
18.31 SOUTHERN CALIFORNIA REPRODUCTIVE CENTER
18.31.1 BUSINESS OVERVIEW
18.32 TENNESSEE REPRODUCTIVE MEDICINE
18.32.1 BUSINESS OVERVIEW
18.33 TEXAS CENTER FOR REPRODUCTIVE HEALTH
18.33.1 BUSINESS OVERVIEW
18.34 THE CENTER FOR FERTILITY AND GYNECOLOGY
18.34.1 BUSINESS OVERVIEW
18.35 THE FERTILITY CENTER OF LAS VEGAS
18.35.1 BUSINESS OVERVIEW
18.36 THE REPRODUCTIVE MEDICINE GROUP
18.36.1 BUSINESS OVERVIEW
18.37 UCLA HEALTH
18.37.1 BUSINESS OVERVIEW
18.38 WESTERN FERTILITY INSTITUTE
18.38.1 BUSINESS OVERVIEW
18.39 WISCONSIN FERTILITY INSTITUTE
18.39.1 BUSINESS OVERVIEW
19 REPORT SUMMARY
19.1 KEY TAKEAWAYS
19.2 STRATEGIC RECOMMENDATIONS
20 QUANTITATIVE SUMMARY
20.1 MARKET BY TYPE
20.2 MARKET BY ART SERVICES
20.2.1 ART SERVICES: SOURCE SEGMENTATION
20.2.2 ART SERVICES: AGE GROUP SEGMENTATION
20.2.3 ART SERVICES: TECHNIQUE SEGMENTATION
20.3 MARKET BY ART DEVICES
20.3.1 ART DEVICES: PRODUCT SEGMENTATION
20.3.2 ART DEVICES: END-USER SEGMENTATION
21 APPENDIX
21.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the total market worth of assisted reproductive technology market in U.S.?
Which are the top manufacturers that hold the major share in assisted reproductive technology market in United States?
What are the key trends in the U.S. assisted reproductive technology (ART) market report?
What are some market opportunities for emerging players to increase their industry share?
What is the anticipated CAGR of the assisted reproductive technology market in the forecast period?
Other RELATED Reports
Infertility Treatment Market - Global Outlook and Forecast 2019-2024
Published : January 2020
 Market - Industry Outlook and Forecast 2021-2026-1625459165.png)
U.S. In-Vitro Fertilization (IVF) Market - Industry Outlook and Forecast 2021-2026
Published : July 2021
